162例药物性肝损伤患者分析

肝脏 ›› 2021, Vol. 26 ›› Issue (3): 243-246.

162例药物性肝损伤患者分析

汪涛, 王学伟, 蒋元烨, 曹勤, 季光

200062 上海中医药大学附属普陀医院消化内科(汪涛、王学伟、蒋元烨、曹勤);上海中医药大学附属龙华医院脾胃病研究所(季光)

收稿日期:2020-04-27 发布日期:2021-04-21
通讯作者: 蒋元烨, Email:yuanye1014@126.com;王学伟,Email:18801809886@163.com
基金资助:
国家自然科学基金青年项目(81703879);上海市卫健委临床研究专项(201840377;201940449);普陀区科委自主创新项目(ptkwws201813);上海市普陀区卫生系统自主创新科研资助项目(ptkwws201806)

Analysis of 162 cases of drug-induced liver injury

WANG Tao¹, WANG Xue-wei¹, JIANG Yuan-ye¹, CAO Qin¹, JI Guang²

Department of Gastroenterology, Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200062,China;Institute of Spleen and Stomach Diseases, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China

Received:2020-04-27 Published:2021-04-21
Contact: JIANG Yuan-ye, Email:yuanye1014@126.com;WANG Xue-wei,Email:18801809886@163.com

摘要/Abstract

摘要： 目的探讨药物性肝损伤(DILI)患者的用药情况及临床特征。方法上海中医药大学附属普陀医院2018年至2019年收治的DILI患者162例,收集既往使用药物,临床特征、实验室指标等临床数据并进行统计学分析。结果 162例DILI患者中,男性60例(37%),女性102例(63%),以40~80岁居多,占141例(87%)。在引起DILI的药物中,中成药及中药汤剂占据首位,其中以首乌、雷公藤、栀子、骨康胶囊及仙灵骨葆胶囊居多。导致肝损伤的西药以心血管系统、抗肿瘤药及结核药物应用居多。162例患者中,乏力117例(72.2%),纳差86例(53.1%),尿黄67例(41.4%)。DILI以肝细胞损伤型最为多见,严重程度分级以1级肝损伤最常见,为112例(69.1%),肝细胞损伤型、胆汁淤积型及混合型患者的ALT、AST、ALP及GGT水平为318.50(177.50-724.00)U/L比117.50(67.00-231.50)U/L比321.00(187.75-747.75)U/L,223.50(118.75-490.75)U/L比132.50(69.00-206.75)U/L比224.00(123.94-670.00)U/L,190.00(122.00-281.75)U/L比289.50(263.00-507.00)U/L比347.00(249.00-560.5)U/L,164.50(89.50-242.25)U/L比309.00(143.50-506.00)U/L比283.00(191.50-574.00)U/L,差异具有统计学意义(均P<0.05)。中药导致的DILI患者的ALT、AST、AKP、TBil及住院天数明显高于西药组为423.00(238.00-728.50)U/L比190.00(97.00-311.00)U/L,345.00(151.25-613.75)U/L比139.00(82.65-223.00)U/L,274.50(207.75-355.25)U/L比220.00(126.00-306.00)U/L,66.5(19.25-114.75)μmol/L比17.00(11.00-33.00)μmol/L,20(15-24.75)比13.00(9.00-17.00),差异均有统计学意义(均P<0.05)。结论 DILI以中老年女性较多;乏力为DILI患者最明显的临床表现,无论是草药还是西药介导的DILI,肝细胞损伤型居多;与西药相比,中药更能引起肝损伤。

关键词: 药物性肝损伤, 用药史, 临床表现

Abstract: Objective To explore the medication situation and clinical characteristics of patients with drug-induced liver injury (DILI), to provide auxiliary judgment for clinicians. Methods The general information of 162 patients with DILI admitted in our hospital from 2018 to 2019 was collected, and clinical data including drugs previously used, clinical characteristics, laboratory data, and statistical analysis. Results Of the 162 patients with DILI, 60 were male (37%) and 102 were female (63%), with the majority in the 40-80 age group, accounting for 141(87%). Among the drugs that caused DILI, we found that Chinese patent medicines and Chinese medicine decoctions occupied the first place, among which Shouwu, Tripterygium wilfordii, Zongzi, Gukang capsules, and Xianling Guzhen capsules were the majority. Antitumor drugs and tuberculosis drugs were mostly used. Among 162 patients, fatigue was the most common in 117 cases (72.2%), followed by anorexia in 86 cases (53.1%) and urinary yellow in 67 cases (41.4%). Hepatocyte injury type was the most common type of DILI, and grade 1 liver injury was the most, accounting for 112 cases (69.1%). The differences in ALT, AST, ALP, and γ-GT levels among the three types of hepatocyte injury, cholestasis, and mixed types were statistically significant [318.50 (177.50-724.00)U/L vs 117.50 (67.00-231.50)U/L vs 321.00 (187.75-747.75)U/L, P=0.000; 223.50 (118.75-490.75)U/L vs 132.50 (69.00-206.75)U/L vs 224.00 (123.94-670.00)U/L, P=0.043; 190.00 (122.00-281.75)U/L vs 289.50 (263.00-507.00)U/L vs 347.00 (249.00-560.5)U/L, P=0.000; 164.50 (89.50-242.25)U/L vs 309.00 (143.50-506.00)U/L vs 283.00 (191.50-574.00)U/L, P=0.000]. In addition, the ALT, AST, APK, TB, and length of hospital stay of DILI patients caused by Chinese medicine were significantly higher than those of western medicine group [423.00 (238.00-728.50)U/L vs 190.00 (97.00-311.00)U/L, P=0.000; 345.00 (151.25-613.75)U/L vs 139.00 (82.65-223.00)U/L, P=0.000; 274.50 (207.75-355.25)U/L vs 220.00 (126.00-306.00)U/L, P=0.009; 66.5 (19.25-114.75)μmol/L vs 17.00 (11.00-33.00)μmol/L, P=0.000; 20 (15-24.75) vs 13.00 (9.00-17.00), P=0.000]. Conclusion DILI was more common in middle-aged and elderly women; and fatigue was the most obvious clinical manifestation of DILI patients. Whether it was herbal medicine or western medicine-mediated DILI, liver cell injury types were mostly; compared with western medicine, traditional Chinese medicine could cause liver damage more.

Key words: Drug-induced liver injury, Medication history, Clinical manifestations

汪涛, 王学伟, 蒋元烨, 曹勤, 季光. 162例药物性肝损伤患者分析[J]. 肝脏, 2021, 26(3): 243-246.

WANG Tao, WANG Xue-wei, JIANG Yuan-ye, CAO Qin, JI Guang. Analysis of 162 cases of drug-induced liver injury[J]. Chinese Hepatolgy, 2021, 26(3): 243-246.

参考文献

[1] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南.临床肝胆病杂志,2015,31:1752 -17692.
[2] Watkins PB,Seligman Pj,Pears Js,et al.Using controlled clinical trails to leran more about acute drug-induced liver injury.Hepatology,2008,48:1680-1689.
[3] Shen T, Liu Y, Shang J, et al.Incidence and etiology of drug-induced liver injury in Mainland China.Gastroenterology,2019,156:2230-2241.
[4] Chitturi S,Farrell GC.Identifying who is at risk of drug-induced liver injury: Is human leukocyte antigen specificity the key.Hepatology, 2011, 53:359-362.
[5] Cho J,Kim L, Li Z,et al.Sex bias in experimental immune-mediated, drug-induced liver injury in BALB/c mice: suggested roles for Tregs, estrogen, and IL-6. PLoS ONE, 2013,8:e61186.
[6] Wong MCS,Huang JLW,George J,et al.The changing epidemiol-ogy of liver diseases in the Asia-Pacific region.Nat Rev Gastroen-terol Hepatol,2019,16:57-73.
[7] Zhou, Yuan,Yang,et al.Epidemiology of drug-induced liver injury in China: a systematic;analysis of the Chinese literature including 21 789 patients.European Journal of Gastroenterology & Hepatology, 2013, 25:825-829.
[8] 朱春雾,王海南,袁继丽,等.445例药物性肝损伤的临床分析.临床肝胆病杂志,2018,34:354-358.
[9] Wang Z,Liang X,Yu J,et al.Non-genetic risk factors and predicting efficacy for docetaxel—drug-induced liver injury among metastatic breast cancer patients.J Gastroenterol Hepatol,2012,27:1348-1352.
[10] Zhang C,Wu Y,Yuan S,et al.Characteristics of drug-induced liver injury in Northeast China:disease spectrum and drug types.Dig Dis Sci,2020,6:1-9.
[11] Pronovost P,Weast B,Schwarz M ,et al.M edication reconcilia-tion:a practicaltoolto reducetherisk ofmedication errors.J Crit Care,2003,18:201-205.
[12] 李娟,张成志,陈庆宪,等.17个省(区、市)56家“三甲”医院医务人员及患者对临床药师的需求及评价调查.中国药房,2018,29:1136-1139.
[13] Rockey DC,Seeff LB,Rochon J,et al.Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method,2010,51:2117-2126.

[1]	王艳, 王昱, 王岚, 田秋菊, 杨瑞园, 李柯鑫, 刘立伟, 鲁一达, 王晓明, 王宇, 欧晓娟, 贾继东, 赵新颜. 抗核抗体阳性程度与药物性肝损伤临床特征及预后的相关性研究[J]. 肝脏, 2021, 26(3): 237-242.
[2]	李青, 周天慧, 莫瑞东, 项晓刚, 赵刚德, 周惠娟, 徐玉敏, 蔡伟, 王晖, 谢青, 赖荣陶. 3型固有淋巴细胞在药物性肝损伤及自身免疫性肝炎患者中的表达具有潜在鉴别价值[J]. 肝脏, 2020, 25(8): 840-844.
[3]	周霞, 孙艳玲, 高银杰, 贺希, 王洪波, 张达利, 刘振文, 刘鸿凌. 肝移植术后患者药物性肝损伤的发生及临床特点[J]. 肝脏, 2020, 25(8): 845-847.
[4]	李梁, 陶应敏, 张学敏, 谢娟, 陈园. 药物性肝损伤患者外周血清HIF1α和COX-2定量检测的临床价值[J]. 肝脏, 2020, 25(8): 848-852.
[5]	杨瑞园, 刘立伟, 罗娟, 李轲鑫, 田秋菊, 王艳, 赵新颜, 贾继东. 药物性肝损伤致急性肝衰竭预测模型的比较研究[J]. 肝脏, 2020, 25(7): 671-675.
[6]	李文庭, 杨亮, 何宏亮, 赵宗豪, 李宜. 药物性肝损伤糖皮质激素应用的时机与指征[J]. 肝脏, 2020, 25(7): 676-678.
[7]	王丽苹, 何婷婷, 朱云, 王仲霞, 王立福, 孙永强, 景婧, 许文涛, 余思邈, 桑秀秀, 田淼, 任岳波, 崔延飞, 王睿林. 两种不同定义标准的慢性药物性肝损伤临床研究[J]. 肝脏, 2020, 25(6): 569-572.
[8]	刘丽艳, 唐晓雯, 胡丽, 张亚蕾, 吴柏霆, 袁继丽, 张雅丽, 刘成海. 113例药物性肝损伤的回顾性分析[J]. 肝脏, 2020, 25(4): 387-389.
[9]	李亚飞, 闫华楠, 韩少静, 郭永泽, 韩书香, 李淑霞, 吉丽, 张宏伟. 老年急性药物性肝损伤临床特征及预后影响因素分析[J]. 肝脏, 2020, 25(3): 319-322.
[10]	周天慧, 莫瑞东, 黄燕, 赖荣陶, 蔡伟, 王晖, 谢青, 汤伟亮. 药物性肝损伤患者血清脂肪酸结合蛋白FABP4水平变化及其临床意义[J]. 肝脏, 2020, 25(2): 158-161.
[11]	寇曦曦. 血清mRNA-122对药物性肝损伤患者早期药物肝毒性评价的价值[J]. 肝脏, 2020, 25(2): 181-183.
[12]	陈书平, 安红军, 郜水菊, 李文丽. 儿童药物性肝损伤的病因、临床特点及预后[J]. 肝脏, 2020, 25(11): 1208-1211.
[13]	田春丽, 梁科峰, 赵玉. 儿童药物性肝损伤的病因及临床特点分析[J]. 肝脏, 2020, 25(1): 31-33.
[14]	熊静平, 张跃新. 110例原发性胆汁性胆管炎的临床特点[J]. 肝脏, 2020, 25(1): 36-38.
[15]	孙慧, 仲海峰, 崔益鸿. 血液透析治疗急性药物性肝损伤的临床疗效观察[J]. 肝脏, 2020, 25(1): 69-70.